Residual minimal disease: breaking the paradigm of complete remission

Lina María Martínez Sánchez; Laura Isabel Jaramillo Jaramillo; Luis Felipe Álvarez Hernández; Felipe Hernández Restrepo; Camilo Ruíz Mejía; Juan Diego Villegas Alzate

2018, Number 1

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2018; 34 (1)

Residual minimal disease: breaking the paradigm of complete remission

Martinez SLM, Jaramillo JLI, Álvarez HLF, Hernández RF, Ruiz MC, Villegas ÁJD

Full text

How to cite this article

Language: Spanish
References: 0
Page: 21-32
PDF size: 212.40 Kb.

ABSTRACT

Hematological malignancies constitute a heterogeneous group of conditions. Residual minimal disease (RMS) refers to the presence of haematological malignancy in patients who are in remission if conventional pathological analyzes are used. RMS has been shown to have prognostic significance in conditions such as: acute myeloid leukemia, chronic myeloid leukemia, multiple myeloma, and acute and chronic lymphoblastic leukemia. Ultrasensitive detection of this condition could allow a better risk stratification and open opportunities for early therapeutic interventions. In the following article there will be a brief review about the prognostic importance of RMS in different hematologic malignancies.